Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats

European Neuropsychopharmacology

Volumn 21, Issue 2, 2011, Pages 205-210

  Crunelle, Cleo L ^a   Schulz, Sybille ^b   de Bruin, Kora ^a   Miller, Michelle L ^a   van den Brink, Wim ^a   Booij, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

123I IBZM storage phosphor imaging; Dopamine receptor; Drug partial agonism; Nicotinic receptor 4 2; Striatum; Varenicline

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRUG VEHICLE; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NICOTINIC RECEPTOR ALPHA4BETA2; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG DEPENDENCE TREATMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SMOKING CESSATION; STRIATE CORTEX;

ANIMALS; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NICOTINIC AGONISTS; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TIME FACTORS; TOBACCO USE DISORDER;

EID: 78751640012     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.11.001     Document Type: Article

References (36)

1. Beukers R.J., Booij J., Weisscher N., Zijlstra F., van Amelsvoort T.A., Tijssen M.A. Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:269-274.
2. Blum K., Chen A.L., Chen T.J., Braverman E.R., Reinking J., Blum S.H., et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor. Biol. Med. Model. 2008, 5:24.
3. Booze R.M., Wallace D.R. Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse 1995, 19:1-13.
4. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch. Gen. Psychiatry 2006, 63:907-915.
5. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2008, CD006103.
6. Chatterjee S., Barlett S.E. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol. Disord. Drug Targets 2010, 9:60-76.
7. Crunelle C.L., Miller M.L., de Bruin K., van den Brink W., Booij J. Varenicline increases striatal dopamine D(2/3) receptor binding in rats. Addict. Biol. 2009, 14:500-502.
8. Crunelle C.L., Miller M.L., Booij J., van den Brink W. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur. Neuropsychopharmacol. 2010, 20:69-79.
9. Dani J.A. Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry 2001, 49:166-174.
10. Ericson M., Löf E., Stomberg R., Söderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J. Pharmacol. Exp. Ther. 2009, 329:225-230.
11. Faessel H.M., Gibbs M.A., Clark D.J., Rohrbacher K., Stolar M., Burstein A.H. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J. Clin. Pharmacol. 2006, 46:1439-1448.
12. Fehr C., Yakushev I., Hohmann N., Buchholz H.G., Landvogt C., Deckers H., et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am. J. Psychiatry 2008, 165:507-514.
13. Ito K., Haga T., Lameh J., Sadée W. Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. Eur. J. Biochem. 1999, 260:112-119.
14. Kim K.M., Valenzano K.J., Robinson S.R., Yao W.D., Barak L.S., Caron M.G. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J. Biol. Chem. 2001, 276:37409-37414.
15. Knol R.J., de Bruin K., de Jong J., van Eck-Smit B.L., Booij J. In vitro and ex vivo storage phosphor imaging of short-living radioisotopes. J. Neurosci. Meth. 2008, 168:341-357.
16. Martinez D., Broft A., Foltin R.W., Slifstein M., Hwang D.R., Huang Y., et al. Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004, 29:1190-1202.
17. Martinez D., Greene K., Broft A., Kumar D., Liu F., Narendran R., et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am. J. Psychiatry 2009, 166:1170-1177.
18. McKee S.A., Harrison E.L., O'Malley S.S., Krishnan-Sarin S., Shi J., Tetrault J.M., Picciotto M.R., Petrakis I.L., Estevez N., Balchunas E. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol. Psychiatry 2010, 66:185-190.
19. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70:801-805.
20. Murray A.M., Ryoo H.L., Gurevich E., Joyce J.N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:11271-11275.
21. Nader M.A., Morgan D., Gage H.D., Nader S.H., Calhoun T.L., Buchheimer N., et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat. Neurosci. 2006, 9:1050-1056.
22. Noble E.P., Blum K., Ritchie T., Montgomery A., Sheridan P.J. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 1991, 48:648-654.
23. high receptors: a possible mechanism for dopamine hypersensitivity. Int. J. Neurosci. 2010, 120:691-697.
24. Obach R.S., Reed-Hagen A.E., Krueger S.S., Obach B.J., O'Connell T.N., Zandi K.S., Miller S., Coe J.W. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos. 2006, 34:121-130.
25. Paxinos G., Watson C. The Rat Brain in Stereotaxic 1986, Academic Press, Coordinates Sydney.
26. Reperant C., Pons S., Dufour E., Rollema H., Gardier A.M., Maskos U. Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area. Neuropharmacology 2010, 58:346-350.
27. Rice M.E., Cragg S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 2004, 7:583-584.
28. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52:985-994.
29. Rollema H., Hajós M., Seymour P.A., Kozak R., Majchrzak M.J., Guanowsky V., et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol. 2009, 78:813-824.
30. Rollema H., Shrikhande A., Ward K.M., Tingley F.D., Coe J.W., O'Neill B.T., et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br. J. Pharmacol. 2010, 160:334-345.
31. Schiffer W.K., Volkow N.D., Fowler J.S., Alexoff D.L., Logan J., Dewey S.L. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 2006, 59:243-251.
32. Tang J., Dani J.A. Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. Neuron 2009, 63:673-682.
33. Verhoeff N.P., Kapucu O., Sokole-Busemann E., van Royen E.A., Janssen A.G. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J. Nucl. Med. 1993, 34:2076-2084.
34. Videbaek C., Toska K., Scheideler M.A., Paulson O.B., Knudsen G.Moos SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse 2000, 38:338-342.
35. Williams K.E., Reeves K.R., Billing C.B., Pennington A.M., Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr. Med. Res. Opin. 2007, 23:793-801.
36. Zhou F.M., Wilson C., Dani J.A. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003, 9:23-36.